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S210 Poster Session Iweeks after adoptive transfer, AML in bone marrow (BM) of
PR1-CTL treated mice decreased 27% (range 21%-32%; p \
0.02) compared to untreated mice, and by 23% (range 4%-47%; p
5 NS) compared to mice receiving PDC. Moreover, AML in the
PB of PR1-CTL treated mice decreased 47% (range 30%-61%, p
\ 0.04) compared to untreated mice, and by 58% (range 48%-
68%; p\0.01) compared to mice receiving PDC. These data justify
clinical studies to determine whether PR1-CTL isolated directly
from UCB can be used to enhance GVL without increased GVHD.153
ANTIGEN PRESENTING CELL-MEDIATED EX VIVO EXPANSION OF
HUMAN UMBILICAL CORD BLOOD CELLS YIELDS SIGNIFICANT EXPAN-
SION OF NATURAL KILLER CELLS WITH ANTI-MYELOMA ACTIVITY
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Background: Allogeneic natural killer (NK) cells are active in vari-
ous hematologic malignancies and may have an important role in
multiple myeloma (MM). Umbilical cord blood (UCB) is a potential
source for allogeneic NK cells and ex vivo expanded UCB-derived
NK (UCB-NK) cells demonstrate activity comparable to that of pe-
ripheral blood-derived NK cells. Here we demonstrate the ability to
expand fresh and frozen UCB-NK cells to clinical grade by novel
techniques using artificial antigen presenting feeder cells modified
to express IL-21 (‘‘K562-cl9-mIL21’’) or IL-15 (‘‘K562-mb-15-
41BBL’’). TheseUCB-NK cells demonstrate appropriate phenotype
and are active against a variety of MM cell lines.
Methods: UCB-NK cells were expanded from 1) fresh or 2) frozen
cord blood units. 1) Fresh cord blood mononuclear cells (CBMCs)
were cultured in 10% human serum albumin media with IL-2 (500
IU/ml) and irradiated K562-cl9-mIL21 feeder cells (2:1 feeder:
CBMCratio) for 21 days.Thereafter, cells were subjected toCD3-im-
munomagnetic depletion. 2) Frozen CBMC’s were grown in a gas
permeable culture flask with IL-2 (100 IU/ml) and irradiated K562-
mb-15-41BBL feeder cells (2:1 feeder: CBMC ratio). Cells were
CD3-depleted on day 7, replated with the same conditions and grown
until day 14. CD3-negative cells were then used as effector cells in
functional assays. Flow cytometry was used to confirmNK cell purity
(C561/CD3- cells) and a standard chromium-51 assay was performed
to determine NK cell cytotoxicity. Targets included K562 cells and
MM cell lines RPMI 8226, ARP-1 and U266.
Results:Expansion of fresh and frozenCBMCs yielded a. 2000 and
. 200 fold expansion ofNKcells, respectively, compared with only 47
fold expansion of fresh CD56-selected cells cultured with IL-2 alone.
After CD3 depletion, fresh and frozen-derived UCB-NK cultures
were comprised of 92% and 94% CD561/CD3- cells respectively.
APC-expanded UCB-NK cells from fresh and frozen cords demon-
strated cytotoxicity against the classic NK cell target K562 as well as
MM cell lines RPMI 8226, ARP-1 and U266.
Conclusions: UCB-NK cells can be expanded ex vivo to clinically
relevant doses for allogeneic NK cell therapy via co-culture with
K562-cl9-mIL21 and K562-mb-15-41BBL feeder cells. Expanded
UCB-NK cells are cytotoxic to K562 cells and various myeloma cell
lines.Further studyof freshand frozen-derivedUCB-NKcells asanad-
junct therapy in stem cell transplantation for myeloma is warranted.154
TRANSFER OF SPECIFIC CELLULAR AND HUMORAL ANTI-TUMOR IMMU-
NITY AFTER STEM CELL TRANSPLANT (SCT) BY VACCINATING STAGE IV
BREAST CANCER PATIENTS WITH Her2/Neu TARGETED T CELLS AND
TRANSFERRING IMMUNE T CELLS INTO THE PATIENTS AFTER SCT
Thakur, A.1, Al-Kadhimi, Z.1, Paul, E.1, Skuba, C.2, Davol, P.3,
Steele, P.1, Rathore, R.3, Ayash, L.1, Abidi, M.1, Uberti, J.1,
Ratanatharathorn, V.1, Lum, L.G.1 1Karmanos Cancer Institute, Detroit,
MI; 2College Veterinary Medicine, East Lansing, MI; 3Roger William
Medical Center, Providence, RIWomen with stage IV metastatic breast cancer (BrCa) have lim-
ited treatment options. Innovative treatment strategies are needed
to improve anti-tumor responses. We have recently shown that spe-
cific T cell immunity can be induced in patients by ‘‘vaccinating’’ the
patients (pts) with infusions of anti-CD3  anti-Her2/neu bispecific
antibody (Her2Bi) armed activated T cells (aATC). This study inves-
tigated whether memory cytotoxic T lymphocytes (CTL) and anti-
body (Ab) directed at BrCa antigens can be transferred into
patients after SCT by evaluating the cytotoxic and Ab responses after
aATC infusions prior to SCT and after SCT. After infusions of
aATC, peripheral blood lymphocytes (PBL) exhibited high levels
of cytotoxicity directed at SK-BR-3 breast cancer cells and high se-
rum levels of Th1 cytokines and IL-12. Three weeks after aATC in-
fusions, ATC were expanded from the second leukopheresis and
cryopreserved for re-infusion after SCT. The expanded ATC from
6 patients at an E:T ratio of 25:1 exhibited cytotoxicity ranging
from 3.7-25.8 (mean13.6%) directed at the SK-BR-3. After SCT,
pts received multiple infusions with a mean total of 54x109 ATC
(range 16-110  109). Cytotoxicity ranged from 4.7 to 70 % from
2 weeks to 12 months post SCT. We tested PBL for the transfer
of humoral immunity after SCT by co-culturing PBL with or with-
out SK-BR-3 tumor cells before IT, mid-IT, 1 month post-IT, pre
and post SCT for in vitro specific anti-SK-BR-3 Ab synthesis.
Anti-SK-BR-3 Abs detected in the culture supernatants by ELISA
ranged from 15 to 40 ng/ml of Abs prior to IT, 150-220 ng/ml
mid-IT and remained high between 70-95 ng/ml at 1 month post-
IT. PBL after SCT showed gradual increases in in vitro Ab synthesis
ranging from 0-10 ng at 1-month post SCT to 70-90 ng by six-
month post SCT upon stimulation with tumor cells. Serum antitu-
mor Ab levels directed at SK-BR-3 increased from 2-4 mg to 10-12
mg post IT and between 6-9 mg after SCT. No dose-limiting
toxicities, delays in engraftment, and life-threatening infections
were observed. These data show that transfer of pre-immunized
ATC and T cells in the stem cell product enhance tumor specific cy-
totoxicity after HDC and PBSCT for breast cancer. Data suggest
that both cellular and Ab responses can be transferred and provide
an anti-tumor immune response early after SCT. This ‘‘vaccinate’’
and ‘‘boost’’ proof-of-principal strategy may be used to design
protocols to enhance anti-tumor activity.155
IMPROVED POST-THAW STABILITY VALIDATION OF PERIPHERAL BLOOD
CELL PRODUCTS UTILIZING THE INTRACELLULAR-LIKE CryoStor
CRYOPRESERVATION SOLUTION, AND PRELIMINARY RESULTS OF
CLINICAL APPLICATION
Fritsch, G.1, Witt, V.1, Matthes, S.1, Dworzak, M.1, Artwohl, M.1,
Clarke, D.2, Mathew, A.J.2 1St. Anna Kinderkrebsforschung, Vienna,
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Collection and cryopreservation of autologous stem cells is a rou-
tine procedure in a variety of malignant diseases. Further, improved
stability of cell products is critical to the development of cell and tis-
sue based therapies as part of the growth in regenerative medicine. A
growing body of evidence indicates that one key method for im-
proved cryopreservation efficacy is the utilization of a hyperos-
motic/intracellular-like cryopreservation media, as opposed to the
traditional use of an isotonic/extracellular-like media such as saline
as the vehicle for the cryoprotectant. In this evaluation of cryopres-
ervationmethods for clinical application, cell samples from apheresis
products were cryopreserved in a conventional isotonic-based freeze
media (CFM; 20% DMSO, 10% human plasma derivate in Ringer
solution) or intracellular-like CryoStor CS10 (CS10; 10% DMSO,
serum-free and protein-free). Immediately after thawing, the recov-
ery ofWBCwas 50.76 14.4% forCFMversus 706 11.6% forCS10
(p\0.001), and that of CD341 cells 81.86 36.1% forCFMand 101
6 16.4% for CS10 (p\ 0.05). In CFM, 20 to 60 min after thawing
there was a dramatic loss in cell viability (-40% to -90%), up to com-
plete clotting in 3/10 samples. By contrast, cells remained viable up
to 60 min after thawing in CS10, and no clotting occurred. Because
of these positive validation results, cryopreservation in the intracel-
lular-like CryoStor CS10 was translated to clinical application for
treatment of hematological malignancies. To date, seven patients
have received autologous stem cells cryopreserved in CS10.
Poster Session I S211Infusions were well tolerated, and both WBC . 1000 and ANC .
500 were reached on day 110.5 (7-11). CryoStor CS10 has demon-
strated benefits in comparison to the previous standard CFM in
terms of cell recovery post-thaw, particularly providing improved
stability after 20 to 60min storage at room temperature (RT) in these
validation experiments, as well as demonstrating clinical tolerance in
initial patient applications. Further data will be collected to validate
the outcome of hematopoietic regeneration after reinfusion.156
INTRATHECAL AUTOLOGOUS TOTAL NUCLEATED CELLS FOR CHILDREN
WITH HIPOXIC/ISCHEMIC BRAIN INJURY
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Background: Perinatal hypoxia/ischemia (H/I) is a brain distur-
bance due to the absence or decrease in oxygen supplementation in
newborns, and represents a leading cause of neurologic injury. Neu-
rological sequelae include cerebral palsy (CP), epilepsy, and cogni-
tive deficit. The reparative, regenerative, and replicative properties
of hematopoietic cells have shown that they could be a potential
treatment of several neurological conditions, including chronic brain
damage. It has been found that hematopoietic cells may be trans-
ported through the cerebrospinal fluid and be delivered more effi-
ciently to the injured area after their introduction in the
subarachnoid space of the spinal cord when compared with the intra-
venous route. The objective of this study is to report the safety and
efficacy of the intrathecal autologous total nucleated cell injection
in the treatment of children with H/I brain injury.
Methods: We included patients with H/I brain injury between 1
month and 8 years old. Patients were evaluated clinically with the
Battelle Developmental Inventory (BDI) and with magnetic reso-
nance images (MRI) before mobilization. Subcutaneous growth-col-
ony stimulation factor was used for 4 days prior to the bone marrow
(BM) harvest. The buffy coat was obtained through centrifugation of
the BM. Total nucleated cells (TNC) were infused through lumbar
puncture, and the red cell concentrate with a residual amount of
TNC was administered intravenously.
Results:Eighteen patients were included, 13 male and 5 female with
a median age of 3 (0 - 8) years and a mean weight of 12.6 (SD 6.7) kg.
A median of 13.3 (1 - 39)  106 CD341 cells in a volume of 7.5 (4 –
10.5) mL were infused intrathecally, and 5.45 (0.5 - 60)  106
CD341 cells in 49.5 (6 – 181) mL were applied intravenously.
Mild anesthetic complications were presented in 2 patients, while
4 had other minor side effects. Twelve patients have reached the
30-day follow-up, showing an increase in BDI equivalent age (11
[1 – 62] vs 11.5 [3 – 74] months, P5 .004).Seven patients have com-
pleted the 6-month follow-up, increasing BDI equivalent age from
14 (1 - 62) to 17 (5 - 73) months (P 5 .016). There have been no
changes yet in any of the MRI comparisons.
Conclusions: This procedure proved to be safe, with minimal side
effects, and may result beneficial in patients’ development. However,
it will be necessary a phase II clinical trial to consider this approach as
a therapeutic option.Table 1. Comparison of the BDI results between days 0 and +30.
Area
Personal/
Social Adaptative Motor skills Com
Day 0 64.5 (3 - 154) 26.5 (4 - 97) 12.5 (3 - 157) 17.5
Day +30 67 (10 - 168) 28.5 (12 - 113) 19 (8 - 155) 19
P value* .013 .054 .005
*Wilcoxon test157
DELICATE BALANCE BETWEEN REGULATION AND STIMULATION AT THE
ANTIGEN PRESENTING CELL SITE DETERMINES THE LIKELIHOOD OF
SUCCESSFUL IN-VITRO PRIMING AND ENRICHMENT OF LEUKEMIA-RE-
ACTIVE T CELLS FROM THE NA€IVE DONOR REPERTOIRE
Jedema, I., Lam, T.S., van de Meent, M., Pots, J., Hoogstraten, C.,
Falkenburg, J.H.F. Leiden University Medical Center, Leiden, Nether-
lands
Although the in-vitro induction of leukemia-reactive T cells from
the na€ıve donor repertoire has been shown to be feasible, the robust-
ness of the procedure is limited. In this study, we investigated the role
of the frequencies of antigen-specific precursor T cells (Tprec) and
regulatory T cells (Treg), the number of antigen presenting cells
(APC), and the number of targeted antigens (Ag) on the ability to
prime, enrich and expand Ag-specific T cells from primary immune
responses in-vitro. Therefore, we developed an in-vitro model sys-
tem allowing quantitative and functional monitoring of Ag-specific
activation and proliferation of individual donor T cells in the first
14 days of the immune response. In this model, we exposed na€ıve
PKH-labeled Tprec to allogeneic APC in different responder/stim-
ulator (R/S) ratios in the presence of different numbers of innocent
bystander cells. Optimal T cell activation was seen at specific
Tprec/S ratios between 1/1 and 1/5, irrespective of the number of in-
nocent bystander cells. Lowering the number of stimulator cells per
Tprec resulted in incomplete activation and proliferation, but more
importantly, exposure to an excess of stimulator cells resulted in in-
duction of activation-induced cell death (AICD) of the Ag-specific
Tprec. Interestingly, when cells with an inferior APC phenotype
(e.g. primary leukemic cells) were used as stimulator cells, activation
curves were of similar shape but shifted towards higher APC
amounts, resulting in optimal stimulation at 1/100 Tprec/S ratios.
Treg were like Tprec attracted to the site of the APC and their acti-
vation further increased their inhibitory potential. Especially when
they were at a numeric advantage, Treg were capable of impairing
Ag-specific Tprec priming. Increasing the number of Ag-specific
Tprec by simultaneous targeting of multiple antigens in combina-
tion with Treg depletion strongly increased the reproducibility of
in-vitro priming and expansion of Ag-specific T cells. In conclusion,
the in-vitro generation of Ag-specific primary immune responses can
only be successfully and reproducibly performed by creating an op-
timal balance at the priming site of the immune response (e.g. the
APC) between the numbers of negative regulators (Treg) and re-
sponding cells (Tprec). Using these insights we developed a standard
operating procedure for the reproducible in-vitro induction and
selection of leukemia-reactive T cells for adoptive transfer using leu-
kemic APC as stimulator cells.158
CYTOTOXIC T CELLS SPECIFIC FOR ADENOVIRUS, BKV, CMV, EBV AND
VZV PRODUCED FOR CLINICAL USE IN IMMUNE RECONSTITUTION
POST ALLOGENEIC STEM CELL TRANSPLANTATION
Blyth, E.1, Clancy, L.E.2, Gaundar, S.1, Simms, R.1, Gottlieb, D.J.1,2,3,4
1University of Sydney,Westmead, NSW, Australia; 2Westmead Hospital,
Westmead, NSW, Australia; 3Westmead Hospital, Westmead, NSW,
Australia; 4University of Sydney, Westmead, NSW, Australia
Introduction: Adoptive immunotherapy using donor-derived cellu-
lar effectors can restore anti-viral immunity after allogeneic stem cell
transplantation. We have developed a method for the production of
a T cell product specific for multiple viruses that does not rely on
EBV transformed cells for stimulation.unication Cognitive Global BDI equivalent age
(5 - 115) 13 (1 - 93) 148 (28 - 576) 11 (1 - 62)
(6 - 115) 14.5 (2 - 104) 156 (60 - 640) 11.5 (3 - 74)
.005 .007 .004 .004
